Review ArticleReview

COVID-19 in cancer patients: risk, clinical features, and management

Cuiwei Liu, Yanxia Zhao, Derick Okwan-Duodu, Reva Basho and Xiaojiang Cui
Cancer Biology & Medicine August 2020, 17 (3) 519-527; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0289

References

  1. 1.↵
    2. Liang W,
    3. Guan W,
    4. Chen R,
    5. Wang W,
    6. Li J,
    7. Xu K, et al.
    Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21: 335–7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Wu Z,
    3. McGoogan JM.
    Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020; 323: 1239–42.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Guan W-J,
    3. Ni Z-Y,
    4. Hu Y,
    5. Liang W-H,
    6. Ou C-Q,
    7. He J-X, et al.
    Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020; 382: 1708–20.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Chen N,
    3. Zhou M,
    4. Dong X,
    5. Qu J,
    6. Gong F,
    7. Han Y, et al.
    Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507–13.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Zhang L,
    3. Zhu F,
    4. Xie L,
    5. Wang C,
    6. Wang J,
    7. Chen R, et al.
    Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31: 894–901.
    OpenUrlPubMed
  6. 6.↵
    2. Dai M,
    3. Liu D,
    4. Liu M,
    5. Zhou F,
    6. Li G,
    7. Chen Z, et al.
    Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020; 10: 783–91.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Sidaway P.
    COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol. 2020; 17: 336.
    OpenUrlPubMed
  8. 8.↵
    2. Kamboj M,
    3. Sepkowitz KA.
    Nosocomial infections in patients with cancer. Lancet Oncol. 2009; 10: 589–97.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.
    2. Li J-Y,
    3. Duan X-F,
    4. Wang L-P,
    5. Xu Y-J,
    6. Huang L,
    7. Zhang T-F, et al.
    Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. 2014; 2014: 286170.
    OpenUrl
  10. 10.
    2. Longbottom ER,
    3. Torrance HDT,
    4. Owen HC,
    5. Fragkou PC,
    6. Hinds CJ,
    7. Pearse RM, et al.
    Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Ann Surg. 2016; 264: 370–7.
    OpenUrlPubMed
  11. 11.↵
    2. Sica A,
    3. Massarotti M.
    Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017; 85: 117–25.
    OpenUrlPubMed
  12. 12.↵
    2. Mehta V,
    3. Goel S,
    4. Kabarriti R,
    5. Cole D,
    6. Goldfinger M,
    7. Acuna-Villaorduna A, et al.
    Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020; 10: 935–41.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Kuderer NM,
    3. Choueiri TK,
    4. Shah DP,
    5. Shyr Y,
    6. Rubinstein SM,
    7. Rivera DR, et al.
    Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395: 1907–18.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Yang K,
    3. Sheng Y,
    4. Huang C,
    5. Jin Y,
    6. Xiong N,
    7. Jiang K, et al.
    Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21: 904–13.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Garassino MC,
    3. Whisenant JG,
    4. Huang L-C,
    5. Trama A,
    6. Torri V,
    7. Agustoni F, et al.
    COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020; 21: 914–22.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Li LQ,
    3. Huang T,
    4. Wang YQ,
    5. Wang ZP,
    6. Liang Y,
    7. Huang TB, et al.
    COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92: 577–83.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Barlesi F,
    3. Foulon S,
    4. Bayle A,
    5. Gachot B,
    6. Pommeret F,
    7. Willekens C, et al.
    Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. AACR Annual Meeting 2020 Online. April 28, 2020; abstr.CT403.
  18. 18.↵
    2. Vuagnat P,
    3. Frelaut M,
    4. Ramtohul T,
    5. Basse C,
    6. Diakite S,
    7. Noret A, et al.
    COVID-19 in breast cancer patients: a cohort at the institute curie hospitals in the Paris area. Breast Cancer Res. 2020; 22: 55.
    OpenUrl
  19. 19.↵
    2. Yang F,
    3. Shi S,
    4. Zhu J,
    5. Shi J,
    6. Dai K,
    7. Chen X.
    Clinical characteristics and outcomes of cancer patients With COVID-19. J Med Virol. 2020. DOI : 10.1002/jmv.25972.
    OpenUrlCrossRef
  20. 20.↵
    2. Huang C,
    3. Wang Y,
    4. Li X,
    5. Ren L,
    6. Zhao J,
    7. Hu Y, et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
    OpenUrlCrossRefPubMed
  21. 21.
    2. Wang D,
    3. Hu B,
    4. Hu C,
    5. Zhu F,
    6. Liu X,
    7. Zhang J, et al.
    Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Xu Z,
    3. Shi L,
    4. Wang Y,
    5. Zhang J,
    6. Huang L,
    7. Zhang C, et al.
    Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8: 420–2.
    OpenUrlPubMed
  23. 23.↵
    2. Shi H,
    3. Han X,
    4. Jiang N,
    5. Cao Y,
    6. Alwalid O,
    7. Gu J, et al.
    Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20: 425–34.
    OpenUrlPubMed
  24. 24.↵
    2. Wang Z,
    3. Yang B,
    4. Li Q,
    5. Wen L,
    6. Zhang R.
    Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71: 769–77.
    OpenUrlPubMed
  25. 25.↵
    2. Wang L-S,
    3. Wang Y-R,
    4. Ye D-W,
    5. Liu Q-Q.
    Review of the 2019 novel coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020; 55: 105948.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Wan S,
    3. Yi Q,
    4. Fan S,
    5. Lv J,
    6. Zhang X,
    7. Guo L, et al.
    Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020; 189: 428–37.
    OpenUrlCrossRef
  27. 27.↵
    2. Yang X,
    3. Yu Y,
    4. Xu J,
    5. Shu H,
    6. Xia J,
    7. Liu H, et al.
    Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8: 475–81.
    OpenUrlPubMed
  28. 28.↵
    2. Wang Y,
    3. Zhang D,
    4. Du G,
    5. Du R,
    6. Zhao J,
    7. Jin Y, et al.
    Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395: 1569–78.
    OpenUrlCrossRefPubMed
  29. 29.
    2. Gao J,
    3. Tian Z,
    4. Yang X.
    Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14: 72–3.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Grein J,
    3. Ohmagari N,
    4. Shin D,
    5. Diaz G,
    6. Asperges E,
    7. Castagna A, et al.
    Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020; 382: 2327–36.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Tobaiqy M,
    3. Qashqary M,
    4. Al-Dahery S,
    5. Mujallad A,
    6. Hershan AA,
    7. Kamal MA, et al.
    Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020; 2: 100061.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Horby P,
    3. Lim WS,
    4. Emberson JR,
    5. Mafham M,
    6. Bell JL,
    7. Linsell L, et al.
    Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2021436.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Ma J,
    3. Xia P,
    4. Zhou Y,
    5. Liu Z,
    6. Zhou X,
    7. Wang J, et al.
    Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol. 2020; 214: 108408.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. No authors listed.
    Cytokine storm drugs move from CAR T to COVID-19. Cancer Discov. 2020; 10: OF8.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    2. Konig MF,
    3. Powell M,
    4. Staedtke V,
    5. Bai R-Y,
    6. Thomas DL,
    7. Fischer N, et al.
    Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. J Clin Invest. 2020; 130: 3345–7.
    OpenUrl
  36. 36.↵
    2. Dong H.
    Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19. Cancer Immunol Immunother. 2020; 69: 911–2.
    OpenUrl
  37. 37.↵
    2. Zhao M.
    Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020; 55: 105982.
    OpenUrlPubMed
  38. 38.↵
    2. Jamilloux Y,
    3. Henry T,
    4. Belot A,
    5. Viel S,
    6. Fauter M,
    7. El Jammal T, et al.
    Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020; 19: 102567.
    OpenUrl
  39. 39.↵
    2. Dranoff G.
    Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4: 11–22.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    2. Cafarotti S.
    Severe acute respiratory syndrome-coronavirus-2 infection and patients with lung cancer: the potential role of interleukin-17 target therapy. J Thorac Oncol. 2020; 15: e101-3.
  41. 41.↵
    2. Fabre J,
    3. Giusiniani J,
    4. Garbar C,
    5. Antonicelli F,
    6. Merrouche Y,
    7. Bensussan A, et al.
    Targeting the tumor microenvironment: the protumor effect of IL-17 related to cancer type. Int J Mol Sci. 2016; 17: 1433.
    OpenUrlCrossRef
  42. 42.↵
    2. Wei X,
    3. Su J,
    4. Yang K,
    5. Wei J,
    6. Wan H,
    7. Cao X, et al.
    Elevations of serum cancer biomarkers correlate with severity of COVID-19. J Med Virol. 2020. DOI: 10.1002/jmv.25957.
    OpenUrlCrossRefPubMed
  43. 43.
    2. Davis AP,
    3. Boyer M,
    4. Lee JH,
    5. Kao SC.
    COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy. 2020; 12: 545–8.
    OpenUrlPubMed
  44. 44.↵
    2. Hanna TP,
    3. Evans GA,
    4. Booth CM.
    Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020; 17: 268–70.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Dockter AG,
    3. Angelos GC.
    Molecular-based alternatives for colorectal cancer screening during the COVID-19 pandemic. Surg Technol Int. 2020; 36: 143–7.
    OpenUrl
  46. 46.↵
    2. Burki TK.
    Cancer care in the time of COVID-19. Lancet Oncol. 2020; 21: 628.
    OpenUrl
  47. 47.↵
    2. Spicer J,
    3. Chamberlain C,
    4. Papa S.
    Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol. 2020; 17: 329–31.
    OpenUrlPubMed
  48. 48.↵
    2. Zacharia BE,
    3. Eichberg DG,
    4. Ivan ME,
    5. Hanft S,
    6. Boockvar JA,
    7. Isildak H, et al.
    Letter: surgical management of brain tumor patients in the COVID-19 era. Neurosurgery. 2020; 87: E197–200.
    OpenUrl
  49. 49.↵
    2. Okwan-Duodu D,
    3. Pollack BP,
    4. Lawson D,
    5. Khan MK.
    Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015; 38: 119–25.
    OpenUrlCrossRefPubMed
  50. 50.↵
    2. Nagar H,
    3. Formenti SC.
    Cancer and COVID-19 – potentially deleterious effects of delaying radiotherapy. Nat Rev Clin Oncol. 2020; 17: 332–4.
    OpenUrl
  51. 51.↵
    2. Ascierto PA.
    Experience in using oncology drugs in patients with COVID-19. AACR Annual Meeting 2020 Online. April 28, 2020; abstr.CT405.
  52. 52.↵
    2. Shah NJ,
    3. Al-Shbool G,
    4. Blackburn M,
    5. Cook M,
    6. Belouali A,
    7. Liu SV, et al.
    Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019; 7: 353.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    2. Bersanelli M.
    Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020; 12: 269–73.
    OpenUrlPubMed
  54. 54.↵
    2. Liao M,
    3. Liu Y,
    4. Yuan J,
    5. Wen Y,
    6. Xu G,
    7. Zhao J, et al.
    Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26: 842–4.
    OpenUrlPubMed
  55. 55.↵
    2. Zhou F,
    3. Yu T,
    4. Du R,
    5. Fan G,
    6. Liu Y,
    7. Liu Z, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–62.
    OpenUrlCrossRefPubMed
  56. 56.↵
    2. Luo J,
    3. Rizvi H,
    4. Egger JV,
    5. Preeshagul IR,
    6. Wolchok JD,
    7. Hellmann MD.
    Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020; 10: 1121–8.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords